| 1 |
Dapagliflozin FDA Label
|
| 2 |
URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4594).
|
| 3 |
Dapagliflozin in Respiratory Failure in Patients With COVID-19 (DARE-19)
|
| 4 |
ClinicalTrials.gov (NCT03249506) Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)
|
| 5 |
ClinicalTrials.gov (NCT02962492) An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes
|
| 6 |
ClinicalTrials.gov (NCT03492580) A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
|
| 7 |
ClinicalTrials.gov (NCT01662999) Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants
|
| 8 |
ClinicalTrials.gov (NCT00839683) Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects
|
| 9 |
ClinicalTrials.gov (NCT00930865) Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects
|
| 10 |
ClinicalTrials.gov (NCT00842556) Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy Subjects
|
| 11 |
ClinicalTrials.gov (NCT00904176) Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects
|
| 12 |
ClinicalTrials.gov (NCT03565458) Gemigliptin, Dapagliflozin, Empagliflozin DDI Study
|
| 13 |
ClinicalTrials.gov (NCT05521984) Targeting Pediatric Brain Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)
|
| 14 |
ClinicalTrials.gov (NCT00859898) Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes
|
| 15 |
ClinicalTrials.gov (NCT00660907) Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients
|
| 16 |
Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013 Feb 20;11:43.
|
| 17 |
ClinicalTrials.gov (NCT01068756) Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects
|
| 18 |
ClinicalTrials.gov (NCT04724837) Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)
|
| 19 |
ClinicalTrials.gov (NCT05986136) Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease
|
| 20 |
ClinicalTrials.gov (NCT02313220) Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight
|
| 21 |
ClinicalTrials.gov (NCT05792540) Clinical Study to Evaluate the Possible Efficacy of Dapagliflozin and Atorvastatin in Patients With Major Depressive Disorders
|
| 22 |
ClinicalTrials.gov (NCT05938712) The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients
|
| 23 |
ClinicalTrials.gov (NCT05776043) Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure
|
| 24 |
ClinicalTrials.gov (NCT04255238) A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone
|
| 25 |
ClinicalTrials.gov (NCT03762850) A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
|
| 26 |
ClinicalTrials.gov (NCT01606007) Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes
|
| 27 |
ClinicalTrials.gov (NCT03074630) Dapagliflozin and Cholesterol Metabolism in Type 2 Diabetes (DM2)
|
| 28 |
ClinicalTrials.gov (NCT05443932) Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients
|
| 29 |
ClinicalTrials.gov (NCT02475070) Vildagliptin Versus Dapagliflozin on Glucagon
|
| 30 |
ClinicalTrials.gov (NCT03089333) Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive Subjects
|
| 31 |
ClinicalTrials.gov (NCT02973477) Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)
|
| 32 |
ClinicalTrials.gov (NCT02719132) Effect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActice
|
|
|
|
|
|
|
